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Abstract
Background—Memantine has been used off-label to treat frontotemporal lobar degeneration
(FTD). A previous 26 week open label study suggested a transient, modest benefit on
neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI).
Methods—We performed a randomized, parallel group, double blind, placebo controlled trial of
20 mg memantine taken orally daily for 26 weeks in FTD. Participants met Neary criteria for
behavioral variant (bvFTD) or semantic dementia (SD) and had characteristic brain atrophy. Use
of cholinesterase inhibitors was prohibited. The objective of the study was to determine whether
memantine is an effective treatment for FTD. Individuals were randomized to memantine or
matched placebo tablets in blocks of two and four. Primary endpoints were the change in total NPI
score and Clinical Global Impression of Change (CGIC) scores after 26 weeks. Secondary
outcomes included a neuropsychological battery, and other cognitive, global and activity of daily
living measures. Clinicaltrials.gov identifier: NCT00545974
Findings—100 subjects were screened, 81 were randomized, 5 (6%) discontinued and 76
completed all visits. Enrollment numbers were lower than planned due to many subjects’
preference to take memantine or cholinesterase inhibitors off-label rather than participate in a
clinical trial. 39 memantine and 42 placebo subjects entered the primary intent to treat analysis.
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There was no effect of memantine treatment on either the NPI (mean difference [MD] 2.2, 95%CI:
−3.9, 8.3, p = 0.47) or CGIC (MD 0, 95%CI: −0.4, 0.4, p = 0.90) after 26 weeks of treatment.
Memantine was generally well tolerated, however there were more frequent cognitive adverse
events in the memantine group.
Interpretation—There was no benefit of memantine treatment in bvFTD or SD. These data do
not support memantine use in FTD.
Funding—Forest Research Institute
Introduction
Frontotemporal lobar degeneration or frontotemporal degeneration (FTD) is a common
cause of dementia in individuals who develop symptoms before age 65. FTD encompasses
three core clinical syndromes, a behavioral variant frontotemporal dementia (bvFTD), and
two primary progressive aphasias (PPA), semantic dementia (SD) and progressive nonfluent
aphasia (PNFA). 1 BvFTD is the most common form of the disease and features prominent
social and behavioral deficits as well as executive dysfunction. SD often begins as an
aphasia, with progressive semantic knowledge loss, but also often features prominent
behavioral abnormalities similar to bvFTD. 2 PNFA presents as a motor speech disorder
with few other cognitive or behavioral impairments. There are no medications approved by
the US Food and Drug Administration (FDA) to treat FTD and only a handful of
randomized, placebo controlled trials have been conducted in FTD.3 Despite the lack of
efficacy data supporting the use of medications approved for the treatment of Alzheimer’s
disease (AD), such medications are frequently prescribed to FTD patients off-label in the
US, with 55% of patients in a recent study using either an acetylcholinesterase inhibitor
(AChI) or memantine. 4
Memantine is approved by the European Medicines Agency and the FDA for the treatment
of moderate-severe AD and has also demonstrated beneficial effects in clinical trials of
vascular dementia, Parkinson’s-related dementias and dementia of mixed etiologies
reviewed in 5). Although the neuropathology and underlying neurotransmitter deficits are
different in FTD than in AD, there is a scientific rationale for using memantine to treat FTD.
First, memantine is believed to act as a non-competitive inhibitor of N-methyl D-aspartate
(NMDA) receptors that may be over-activated in a variety of neurodegenerative diseases,
including FTD. 5 Second, analyses of data from clinical trials of memantine in AD found
clear benefits on a variety of abnormal behaviors as assessed by the Neuropsychiatric
Inventory (NPI). 6 Since many of these behaviors are prominent features of FTD, memantine
might also be predicted to improve these deficits. Third, a number of open label treatment
studies in bvFTD and SD have demonstrated symptomatic improvements with memantine
treatment. 7,8 In one of these studies, we found that initiation of memantine therapy was
associated with a transient improvement in behavior as measured by the NPI 9 in bvFTD and
SD subjects. 8 Since the transient improvement in NPI scores might have been attributable
to a placebo effect or an effect of memantine treatment, the current study tested the
hypothesis that memantine would improve or stabilize behavior as measured by the NPI and




Patients were recruited from nine US academic dementia research centers with expertise in
the diagnosis of FTD including the University of California, San Francisco (UCSF) and Los
Angeles (UCLA), the Mayo Clinic, Rochester and Jacksonville, Northwestern University
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Medical Center, Case Western Reserve Medical Center, University of North Carolina, Johns
Hopkins University and the University of Pennsylvania. Study visits occurred between
December, 2007 and May, 2012. Because this was a follow-up study to a 26 week open-
label study of memantine that showed a similar pattern of changes in bvFTD and SD, but not
PNFA, 9 the current study only included subjects with bvFTD or SD. 1 Individuals with
FTD-motor neuron disease were included if motor impairments did not interfere with study
procedures. Individuals had to be between 40–80 years of age and have a Mini-Mental State
Exam (MMSE) score of ≥ 15 at screening. To exclude cases with slowly progressive bvFTD
(bvFTD phenocopy) all subjects had a CT or MRI scan of brain within 24 months of
randomization consistent with a diagnosis of bvFTD or SD. 11 All subjects had a reliable
caregiver who could accompany them to study visits. Exclusion criteria included a diagnosis
of PNFA, use of memantine, AChI, antipsychotic agents, valproate, lithium or
benzodiazepines within four weeks prior to randomization. Use of AChI was prohibited due
to potential confounding effects on memantine efficacy and reported adverse reactions in
FTD. 12,13 If behavioral symptoms became difficult to control after the baseline visit,
individuals were allowed to take an atypical antipsychotic medication (olanzapine,
quetiapine or risperidone). Antidepressant use was allowed, if the dose had been stable for
one month prior to randomization. Other exclusion criteria included evidence of disorders
that preclude diagnosis of FTD. 1 Written informed consent was obtained from the subject
and the subject’s caregiver in accordance with local IRB regulations. Clinicaltrials.gov
identifier: NCT00545974.
Randomization and blinding
Subjects were randomized to memantine 10 mg twice daily or identical placebo tablets
lacking memantine, that were packaged into kits (one per subject) of multiple blister packs
(one week of treatment per pack). All subjects and study personnel were blinded to
treatment assignment. Randomization codes were generated by an unblinded UCSF
pharmacist (S.F.) using the Excel (Microsoft) random number generator in blocks of 2 and 4
subjects.
Study procedures
Each subject participated in six study visits over approximately 35 weeks. After the
screening visit, a randomization/baseline visit occurred within 35 days, during which initial
study medication was dispensed. Individuals were titrated to the full dose of 10 mg
memantine or placebo taken orally twice daily, by 5 mg per week, reaching the full dose at
week four. Subjects returned at weeks six, 12 and 26 (or early termination) for safety and
efficacy assessments. In addition to the in-person visits, on weeks three, nine and 18,
individuals received a phone call to assess adverse events and study medication compliance.
After the week 26 visit, the study medication was stopped, and individuals returned for a 30
day off drug safety assessment. Compliance was assessed by counting study medication
remaining in the blister packs. All outcome measures were assessed at baseline and week 26,
with a subset of measures collected at weeks 6 and 12. Adverse events were grouped by
Medical Dictionary for Regulatory Activities (MedRA) system organ class
(www.meddramsso.com). Serious Adverse Events (SAEs) were defined as those leading to
hospitalization or death.
Outcome measures
The primary outcomes were the NPI and CGIC. The NPI is a measure that assesses 12
neuropsychiatric abnormalities that reveals severe abnormalities in FTD. 9 The CGIC is a
seven point categorical scale that gives a global impression of change from baseline.
Secondary efficacy assessments included the clinical dementia rating sum of boxes (CDR-
SB-FTD), with behavioral comportment, personality and language domains added to better
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capture FTD-related deficits; 14 the MMSE;8 the Functional Activities Questionnaire
(FAQ) ; 15 Texas Functional Living Scale (TFLS) a performance-based assessment of
capacity to perform ADLs;16 the Executive Interview (EXIT25), a neuropsychological
composite to test executive function, 17 a modified Unified Parkinson’s Disease Rating
Scale (UPDRS); 8 the time to initiation of antipsychotic therapy; and a neuropsychological
battery, including a California Verbal Learning Test, category fluency, phonemic fluency, a
15 item Boston Naming Test (BNT), a modified Trails set-shifting task, backward digit span
and the Digit Symbol as previously described. 14 Tertiary outcomes were the Zarit Burden
Interview (ZBI), a 22 item questionnaire used to measure caregiver burden 18 and subject
weight in Kg (since FTD patients often gain weight).
Sample Size Estimate
We based our sample size calculation on a comparison of changes in NPI from baseline to
follow-up between the memantine treatment and placebo groups using a two sample t-test.
We hoped to detect a medium effect size of half a standard deviation. 19 Standard power
calculations for two sample t-tests (α = 0.05) with a standard deviation of 2.2 (half of 4.4
from 8) show that a sample of 65 per group would provide power greater than 80% power to
detect this difference.
Statistical analysis
Primary and secondary outcomes were analyzed using an intent-to-treat (ITT) approach that
included all subjects who received at least one dose of medication and had a post-baseline
efficacy assessment. We used a repeated measures approach to assess the difference in
changes over time in the repeated primary (NPI) and secondary outcomes between the
memantine and placebo groups, that is, the time by treatment group interaction. Specifically,
for each subject, we computed changes in outcomes between baseline and the 26 week
follow up and assessed the magnitude of the difference in these changes using linear
regression methods. Analyses were repeated using gender as a covariate. It was decided
post-hoc to reduce the CGIC values to “improved, no change or worsened” due to the very
few number of responses outside the middle 3 values. Week 26 CGIC values were compared
using a Mann-Whitney U test. Exploratory analyses in each FTD subtype and observed
cases (OC), subjects who completed all four efficacy visits, were conducted to investigate
potential sources of bias in the ITT analyses. Finally, differences in outcome measures at
individual time points were compared using least squares means with a two-sample t-test,
and differences in adverse event frequencies were analyzed using Chi square tests. Analyses
were performed using SAS 9.3 (SAS Inc., Cary, NC) or Stata 12 (StataCorp, College
Station, TX).
Results
100 patients were assessed for eligibility and 81 patients (64 bvFTD and 17 SD) were
randomly assigned to memantine (n=39) or placebo (n=42; Figure 1). Five patients (2
memantine, 3 placebo) discontinued treatment prior to the end of the study. The planned
enrollment for the study was 140 subjects. Despite randomization, there was a greater
percentage of men in the placebo group (Table 1; P=0.01). There were no other baseline
differences in demographic variables, concomitant medication use, or outcome measures
(Supplementary Data). 17 memantine and 13 placebo subjects took 100% of the study
medication (p=0.24); for the remaining subjects, mean study medication compliance was
95.6% (95%CI: 92.3, 97.3) in the placebo group and 94.8% (93.0, 98.2) in the memantine
group (p = 0.65).
Boxer et al. Page 5














In the ITT analysis there were no differences between the memantine and placebo groups on
the change in total NPI or CGIC scores after 26 weeks (Table 2). The mean difference in
change in NPI score from baseline to week 26 was 2.2 (95%CI: −3.9, 8.3, P=0.47; Figure
2A). Adjusting for baseline gender differences post-hoc did not alter the result
(Supplementary Table 1). The CGIC showed that at week 26, 27 subjects worsened, 8
remained stable and two improved in the memantine group, whereas 29 subjects worsened, 8
remained stable and four improved in the placebo group (p=0.90; Figure 2B).
Secondary outcomes
No treatment effect was observed on the functional outcome measures, the CDR-SB-FTD,
FAQ and TFLS. CDR-SB-FTD scores increased similarly in both groups by 1.5 (0.8, 2.1)
points over 26 weeks (Figure 3). Performance on the FAQ and TFLS declined similarly in
the placebo and memantine groups (p=0.67).
The memantine group displayed worse neuropsychological performance than the placebo
group on tests of naming (BNT) and processing speed (Digit Symbol; Figure 4, Table 2).
There were no differences on other neuropsychological composite (MMSE and EXIT25),
and individual test scores (Table 2). Consistent with the effects we observed on
neuropsychological tests, there were numerically more cognitive AE’s (confusion, memory
loss, language disorders; six vs. one; p= 0.056, supplementary table 4) in the memantine
group than the placebo group, whereas the opposite was true for psychiatric AE’s (p=0.03).
Two individuals experienced a SAE in the placebo group and one individual experienced
two SAEs in the memantine group. SAEs were not judged to be treatment related. There
were no differences in UPDRS or other safety assessments (Table 3). Since only three
subjects began an antipsychotic medication during the study (Supplementary Data), time to
antipsychotic use was not analyzed.
Tertiary outcomes
There was no treatment effect on caregiver burden (ZBI, p=0.13) or change in weight.
Exploratory (post-hoc) analyses
Because we had previously observed a transient improvement in NPI scores in an open-label
memantine treatment study, 8 we examined differences in NPI scores at individual time
points and found a transient improvement (MD 5.9, 95%CI: 4.2, 7.6) at week six (p=0.01)
that converged with changes in the placebo group at weeks 12 and 26 (p>0.30; Figure 2A).
We also investigated whether the effects we found on the BNT and digit symbol test were
related to FTD subtype. When analyzed separately, BNT performance was worse in both the
bvFTD and SD groups after 26 weeks (Supplementary Figure 1). On the Digit Symbol test,
there was a small improvement in performance in the placebo group after 26 weeks of
treatment, whereas the memantine group declined (MD: 8.1, 95%CI: 1.1, 15.1, P < 0.001;
Figure 4B).
Discussion
We found no benefit of 20 mg daily memantine treatment in FTD on either of the primary
outcome measures, the NPI or the CGIC, after 26 weeks of treatment. There was evidence of
worse cognitive performance on tests of naming (BNT) and processing speed (Digit
Symbol) associated with memantine treatment, and a trend towards more cognitive adverse
events. However, the worse neuropsychological performance in the memantine group was
not associated with a difference in the rate of decline in activities of daily living as measured
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by CDR-SB-FTD, FAQ and TFLS. Although memantine was safe and well tolerated in
FTD, our results do not support a claim of benefit for memantine treatment in FTD patients.
Since approximately 30% of bvFTD patients in the US take memantine,4 our findings have
immediate public health implications.
Our results are similar to those from a recent 52 week randomized placebo controlled trial of
memantine in 49 subjects with bvFTD that also demonstrated no benefit on the primary
outcome, the Clinician’s Interview-Based Impression of Change (similar to the CGIC) or the
NPI.20 Like the previous study, a major limitation of the current study was that we failed to
enroll the planned number of subjects, which may have limited our ability to detect a
treatment effect. This under-enrollment was due to many potential subjects’ preference to
take memantine (and in many cases an AChI as well) rather than participate in a clinical trial
during which they risked being randomized to placebo. Unfortunately, altering the
enrollment criteria to allow use of these medications would have prevented us from testing
our hypothesis that memantine might have benefit in the treatment of FTD. Instead, to
improve recruitment, sites stressed equipoise regarding the efficacy of memantine when
recruiting subjects. A second limitation of the study was the small size of the SD group,
which limits the generalizability of our results to this FTD syndrome. Finally, since this trial
was designed, a number of rating scales that better capture FTD-specific behaviors have
been developed that might have been more sensitive to potential benefits of memantine than
those we employed (reviewed in 21).
Despite these limitations, we believe that our study provides strong evidence that memantine
is not an effective treatment for FTD. First, in an exploratory analysis, there was a transient
improvement in NPI scores after six weeks of treatment that was similar in magnitude and
time course to what we observed in a previous open-label treatment study (n= 34 bvFTD and
SD patients) 8 suggesting that the pattern of changes observed on the NPI (Figure 2) did not
arise by chance. Second, we conducted a study-level meta-analysis, combining six month
CGIC data from the current study and 12 month CIBICplus data presented in the manuscript
from the previous bvFTD clinical trial, 20 for a combined total of n=64 placebo and n=55
memantine cases. This meta-analysis found no difference between placebo and memantine
on the combined global impression (MD = 0.082, 95%CI: −0.18, 0.34; P = 0.553). Third, we
observed worse visuomotor and naming function in the memantine group in the pre-
specified analyses (Table 2). Consistent with these findings, there was a greater number of
cognitive adverse events in the memantine group (Table 3). Finally, the rate of decline in
CDR-SB-FTD scores was identical in both groups, and numerically, FAQ scores appeared
to decline more rapidly in the memantine group at week 12 (Figure 3), although this was an
exploratory finding that should be interpreted with caution.
We found fewer psychiatric (behavioral) side effects in the memantine group than the
placebo group (Table 3). The simplest explanation for the divergent effects of memantine
we observed in this study would be that memantine had a general suppressive effect on
attention and cognition that led to less distressing behavior as well a reduced ability to
perform visuomotor processing and lexical retrieval tasks.
Our study suggests that FTD patients may respond differently to memantine than other
forms of dementia, underscoring the importance of accurate diagnosis. In moderate-severe
AD, memantine has demonstrated benefits on global and cognitive function alone or in
combination with donepezil. 12 Although a pilot study of memantine in PPA (not
differentiated by subtype) suggested a modest benefit of treatment on the Western Aphasia
Battery, 22 some forms of PPA are due to underlying AD pathology which could explain this
finding. Clinical trials of memantine for VaD also suggest a modest benefit on cognition in
patients with mild to moderate impairment. 23 Two clinical trials of memantine in
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Parkinson’s-related dementia demonstrated efficacy for treatment of cognitive and
behavioral symptoms.24,25 We speculate that the lack of benefit of memantine treatment in
FTD could reflect a different pattern of neurotransmitter abnormalities in this disorder.3
This is the largest randomized placebo controlled trial conducted in FTD to date. In addition
to the implications for the current treatment of FTD, we demonstrate that clinical trials are
feasible in this disorder. Since approximately half of all FTD cases have underlying tau
pathology, as in AD, it has been suggested that tau-directed therapeutics might eventually be
used in both disorders.26 We found that the rate of decline as measured by the CDR-SB-
FTD was approximately twice as fast as has been reported for the CDR-SB in AD. 27 The
more rapid progression of FTD as compared to AD may allow for faster clinical trials in
FTD than in AD to test the efficacy of therapies targeting proteins such as tau that are
common to both disorders. 21 This study provides clear evidence of a lack of efficacy of
memantine treatment for mild to moderate FTD, highlighting the urgent need to develop
more effective FTD therapeutics.
Research in Context
Systematic review
We searched Pubmed using the following terms: “memantine,” and “frontotemporal
dementia,” “semantic dementia,” “frontotemporal lobar degeneration,” “Pick’s,” “FTD,”
“FTLD,” “primary progressive aphasia,” “PPA,” “corticobasal,” or “aphasia.” We included
randomized, placebo-controlled trials in FTD or a related disorder that involved memantine.
We identified one prior RCT in bvFTD21 and one in PPA (not differentiated by subtype). 22
We conducted a study-level meta-analysis, combining six month CGIC data from the current
study and 12 month data from Table 4 from the previous bvFTD clinical trial 21, but not the
PPA trial because it was not limited to SD, for a combined total of n=64 placebo and n=55
memantine cases. There was no difference between placebo and memantine on the
combined global impression scores (MD = 0.082, 95%CI: −0.18, 0.34; p = 0.553, Mann-
Whitney U).
Interpretation
This study confirms the lack of benefit of memantine for treatment of FTD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 2. Primary outcome variables
(A) Change from baseline of total Neuropsychiatric Inventory (NPI) scores from the intent
to treat population are shown with p values for a paired t test at each study visit. In the
repeated measures analysis there was no group difference (p = 0.39). (B) Clinician’s Global
Impression of Change (CGIC) values are shown at week 26 for n = 76 subjects who
completed this visit. Only improved = “slightly improved (3)”, no change = “no change (4)”
and Worsened = “slightly worsened (5)” are shown since no other values were recorded.
Using a Mann Whitney test there was no difference in CGIC distributions (p = 0.90).
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Figure 3. Functional rating scales
(A) Change from baseline Functional Activities Questionnaire (FAQ) scores in the intent to
treat population. (B) Change from baseline in Clinical Dementia Rating sum of boxes
(CDR-SB-FTD) scores.
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Figure 4. Neuropsychological tests
(A) Change from baseline modified Boston Naming Test (BNT). (B) Change from baseline
Digit Symbol Substitution Test scores.
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Table 2
Mean differences in longitudinal change from baseline
Measure
Difference 95% CI P value
 Primary outcomes
NPI 2.2 −3.9, 8.3 0.47
CGIC 0 −0.4, 0.4 0.90
 Secondary outcomes Global
CDR-SB-FTD 0 −0.9, 0.9 0.99
FAQ −1.5 −4.0, 1.0 0.23
TFLS 0.9 −1.7, 3.5 0.49
 Cognitive
MMSE 0.1 −1.3, 1.5 0.69
EXIT25 −1.2 −3.8, 1.4 0.34
Boston Naming Test 2.2 0.7, 3.6 0.004
Category fluency 0.4 −1.7, 2.4 0.72
Digits backwards −0.3 −0.8, 0.2 0.28
Digit symbol 8.1 1.1, 15.1 0.024
Letter fluency −0.2 −1.5, 1.1 0.75
 Motor
UPDRS −0.3 −3.0, 2.4 0.83
 Tertiary outcome
ZBI 22 1.6 −2.0, 5.3 0.38
Mean difference is placebo - memantine group.

















Body Class/Preferred Term N % N %
Body as Whole
 Fatigue 1 2.4 1 2.6
Cognitive Disorders
 Language Problems 0 0.0 3 7.7
 Memory Loss 0 0.0 2 5.1
Gastrointestinal Disorders
 Diverticulitis 2 4.8 0 0.0
 Nausea 3 7.1 0 0.0
Injury
 Abrasion 0 0.0 2 5.1
 Fall 2 4.8 5 12.8
Nervous System Disorders
 Back Pain 0 0.0 2 5.1
 Dizziness 2 4.8 2 5.1
 Headache 3 7.1 1 2.6
Psychiatric Disorders
 Agitation 2 4.8 0 0.0
 Behavioral Rigidity 1 2.4 1 2.6
 Inappropriate Sexual Behavior 4 9.5 0 0.0
 Insomnia 4 9.5 0 0.0
 Obsessive Compulsive Symptoms 1 2.4 2 5.1
 Somnolence 1 2.4 1 2.6
Renal and Urinary Disorders
 Urinary Tract Infection 0 0.0 2 5.1
 Urinary Frequency 1 2.4 1 2.6
Respiratory Disorders
 Upper Respiratory Infection 0 0.0 2 5.1
Skin and Subcutaneous Tissue Disorders
 Rash 1 2.4 1 2.6
Adverse events (AEs, all severities combined), occurring in two or more individuals (N), in either group combined, and percent of ITT population
(%) in each group. AEs occurring in only one individual are not shown. A complete list of adverse events is given in the Supplementary Materials
(Supplementary Table 4).
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